Bionomics Limited/fi Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Neuphoria Therapeutics Director David Ian Wilson was granted 8,537 Restricted Stock Units as part of the company's annual remuneration policy.
Neuphoria Therapeutics Inc. director Peter Miles Winston Davies was granted 8,537 restricted stock units as part of the company's annual remuneration policy.
Neuphoria Therapeutics Inc. Director Alan Fisher received a grant of 17,073 Restricted Stock Units as part of the company's annual remuneration policy.
Neuphoria Therapeutics Director Jane Ryan was granted 8,537 Restricted Stock Units as part of the company's annual remuneration policy, vesting by December 2026.
Lynx1 Capital Management LP and Weston Nichols acquired 639,110 shares of Neuphoria Therapeutics Inc. common stock for approximately $3.28 million.
Neuphoria Therapeutics Inc. President and CEO, Spyros Papapetropoulos, was granted 34,559 employee stock options with an exercise price of $8.27.
Neuphoria Therapeutics' CEO, Spyros Papapetropoulos, files an amended Form 4/A to correct a clerical error in the reporting of stock option acquisitions.
Neuphoria Therapeutics CEO Spyros Papapetropoulos was granted 270,000 employee stock options on April 16, 2025, according to a Form 4 filing.
Form 4: Neuphoria Therapeutics Director, Peter Miles Winston Davies, Acquires Restricted Stock Units
Director Peter Miles Winston Davies acquired 6,783 Restricted Stock Units (RSUs) of Neuphoria Therapeutics Inc. on April 16, 2025.
Form 4: Neuphoria Therapeutics Director Jane Ryan Reports Acquisition and Disposal of Restricted Stock Units
Director Jane Ryan reports transactions involving restricted stock units of Neuphoria Therapeutics Inc.
Director David Ian Wilson reports acquisition of restricted stock units in Neuphoria Therapeutics.
Director Alan Fisher reports acquisition of restricted stock units in Neuphoria Therapeutics.